{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:50:20Z","timestamp":1790934620383,"version":"4.1.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2000,11,7]]},"abstract":"<jats:p>\n                    <jats:italic>Background<\/jats:italic>\n                    \u2014This double-blind, multicenter, placebo-controlled study determined the efficacy and safety of dofetilide in converting atrial fibrillation (AF) or atrial flutter (AFl) to sinus rhythm (SR) and maintaining SR for 1 year.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Methods and Results<\/jats:italic>\n                    \u2014Patients with AF or AFl (n=325) were randomized to 125, 250, or 500 \u03bcg dofetilide or placebo twice daily. Dosages were adjusted for QTc response and, after 105 patients were enrolled, for calculated creatinine clearance (Cl\n                    <jats:sub>Cr<\/jats:sub>\n                    ). Pharmacological cardioversion rates for 125, 250, and 500 \u03bcg dofetilide were 6.1%, 9.8%, and 29.9%, respectively, versus 1.2% for placebo (250 and 500 \u03bcg versus placebo;\n                    <jats:italic>P<\/jats:italic>\n                    =0.015 and\n                    <jats:italic>P<\/jats:italic>\n                    &lt;0.001, respectively). Seventy percent of pharmacological cardioversions with dofetilide were achieved in 24 hours and 91% in 36 hours. For the 250 patients who successfully cardioverted pharmacologically or electrically, the probability of remaining in SR at 1 year was 0.40, 0.37, 0.58 for 125, 250, and 500 \u03bcg dofetilide, respectively, and 0.25 for placebo (500 \u03bcg versus placebo,\n                    <jats:italic>P<\/jats:italic>\n                    =0.001). Two cases of torsade de pointes occurred, 1 on day 2 and the other on day 3 (0.8% of all patients given active drug); 1 sudden cardiac death, classified as proarrhythmic, occurred on day 8 (0.4% of all patients given active drug).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions<\/jats:italic>\n                    \u2014Dofetilide, a new class III antiarrhythmic agent, is moderately effective in cardioverting AF or AFl to SR and significantly effective in maintaining SR for 1 year. In-hospital initiation and dosage adjustment based on QTc and Cl\n                    <jats:sub>Cr<\/jats:sub>\n                    are necessary to minimize a small but nonnegligible proarrhythmic risk.\n                  <\/jats:p>","DOI":"10.1161\/01.cir.102.19.2385","type":"journal-article","created":{"date-parts":[[2012,6,11]],"date-time":"2012-06-11T20:42:29Z","timestamp":1339447349000},"page":"2385-2390","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":358,"title":["Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter"],"prefix":"10.1161","volume":"102","author":[{"given":"Steven","family":"Singh","sequence":"first","affiliation":[{"name":"From Veterans Affairs Medical Center, Washington, DC (S.S.); James A. Haley Medical Center (R.G.Z.), Tampa, Fla; Cardiology Associates Medical Group of East San Diego, Inc (L.Y.), San Diego, Calif; the Division of Cardiology, University of California\u2013Irvine Medical Center (M.A.B.); the Division of Cardiology, University of California\u2013San Diego Medical Center (G.K.F.); the Division of Cardiology, Presbyterian Hospital of Dallas (M.B.), Dallas, Tex; and Pfizer Inc (C.B.B.), Groton, Conn."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Zoble","sequence":"additional","affiliation":[{"name":"From Veterans Affairs Medical Center, Washington, DC (S.S.); James A. Haley Medical Center (R.G.Z.), Tampa, Fla; Cardiology Associates Medical Group of East San Diego, Inc (L.Y.), San Diego, Calif; the Division of Cardiology, University of California\u2013Irvine Medical Center (M.A.B.); the Division of Cardiology, University of California\u2013San Diego Medical Center (G.K.F.); the Division of Cardiology, Presbyterian Hospital of Dallas (M.B.), Dallas, Tex; and Pfizer Inc (C.B.B.), Groton, Conn."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Yellen","sequence":"additional","affiliation":[{"name":"From Veterans Affairs Medical Center, Washington, DC (S.S.); James A. Haley Medical Center (R.G.Z.), Tampa, Fla; Cardiology Associates Medical Group of East San Diego, Inc (L.Y.), San Diego, Calif; the Division of Cardiology, University of California\u2013Irvine Medical Center (M.A.B.); the Division of Cardiology, University of California\u2013San Diego Medical Center (G.K.F.); the Division of Cardiology, Presbyterian Hospital of Dallas (M.B.), Dallas, Tex; and Pfizer Inc (C.B.B.), Groton, Conn."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Brodsky","sequence":"additional","affiliation":[{"name":"From Veterans Affairs Medical Center, Washington, DC (S.S.); James A. Haley Medical Center (R.G.Z.), Tampa, Fla; Cardiology Associates Medical Group of East San Diego, Inc (L.Y.), San Diego, Calif; the Division of Cardiology, University of California\u2013Irvine Medical Center (M.A.B.); the Division of Cardiology, University of California\u2013San Diego Medical Center (G.K.F.); the Division of Cardiology, Presbyterian Hospital of Dallas (M.B.), Dallas, Tex; and Pfizer Inc (C.B.B.), Groton, Conn."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory K.","family":"Feld","sequence":"additional","affiliation":[{"name":"From Veterans Affairs Medical Center, Washington, DC (S.S.); James A. Haley Medical Center (R.G.Z.), Tampa, Fla; Cardiology Associates Medical Group of East San Diego, Inc (L.Y.), San Diego, Calif; the Division of Cardiology, University of California\u2013Irvine Medical Center (M.A.B.); the Division of Cardiology, University of California\u2013San Diego Medical Center (G.K.F.); the Division of Cardiology, Presbyterian Hospital of Dallas (M.B.), Dallas, Tex; and Pfizer Inc (C.B.B.), Groton, Conn."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Berk","sequence":"additional","affiliation":[{"name":"From Veterans Affairs Medical Center, Washington, DC (S.S.); James A. Haley Medical Center (R.G.Z.), Tampa, Fla; Cardiology Associates Medical Group of East San Diego, Inc (L.Y.), San Diego, Calif; the Division of Cardiology, University of California\u2013Irvine Medical Center (M.A.B.); the Division of Cardiology, University of California\u2013San Diego Medical Center (G.K.F.); the Division of Cardiology, Presbyterian Hospital of Dallas (M.B.), Dallas, Tex; and Pfizer Inc (C.B.B.), Groton, Conn."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Clare B.","family":"Billing","sequence":"additional","affiliation":[{"name":"From Veterans Affairs Medical Center, Washington, DC (S.S.); James A. Haley Medical Center (R.G.Z.), Tampa, Fla; Cardiology Associates Medical Group of East San Diego, Inc (L.Y.), San Diego, Calif; the Division of Cardiology, University of California\u2013Irvine Medical Center (M.A.B.); the Division of Cardiology, University of California\u2013San Diego Medical Center (G.K.F.); the Division of Cardiology, Presbyterian Hospital of Dallas (M.B.), Dallas, Tex; and Pfizer Inc (C.B.B.), Groton, Conn."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-6-199403150-00001"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.94.7.1585"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0022-3565(25)10827-6","volume":"262","year":"1992","unstructured":"Carmeliet E. Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther. 1992;262:809\u2013817.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90996-C"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90038-1"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199303000-00024"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909163411201"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00183-0"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.82.4.2144796"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1998.tb00103.x"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09145-3"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)08171-8"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90003-6"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.102.19.2385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T16:28:27Z","timestamp":1743352107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.102.19.2385"}},"subtitle":["The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study"],"short-title":[],"issued":{"date-parts":[[2000,11,7]]},"references-count":13,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2000,11,7]]}},"alternative-id":["10.1161\/01.CIR.102.19.2385"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.102.19.2385","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11,7]]},"assertion":[{"value":"2000-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-06-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-11-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}